Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 3/20 | 0.86 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.86 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL7631977 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL19689578 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL2534545 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL8676988 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL5672134 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL156565 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL593326 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL669805 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL15899693 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL2360021 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102205201-A | Recovering process for desulphurized ammonium sulfate/magnesium sulfate | YUBIN ZHAO | 2011-10-05 | — | — | CN | claimed |
| US-3943078-A | Soil penetrating, compacting and cementing composition | JAMES THOMAS HOWARD | 1976-03-09 | — | — | US | claimed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| WO-2024127350-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| CN-220779710-U | Solid dry desulfurization and dust removal integrated device | 安徽明光虹源生物质有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-114177949-B | Method for improving abrasion resistance of windward end of honeycomb denitration catalyst unit | 安徽元琛环保科技股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-114177949-B | Method for improving abrasion resistance of windward end of honeycomb denitration catalyst unit | 安徽元琛环保科技股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| US-5226877-A | METHOD AND APPARATUS FOR PREPARING FIBRINOGEN ADHESIVE FROM WHOLE BLOOD | BAXTER INTERNATIONAL, INC. | 1993-07-13 | — | — | US | disclosed |
| EP-0288190-B1 | IMPROVEMENTS IN OR RELATING TO LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1992-07-08 | — | — | EP | disclosed |
| WO-1991000046-A2 | METHOD AND APPARATUS FOR PREPARING FIBRINOGEN ADHESIVE FROM WHOLE BLOOD | EPSTEIN GORDON (US) | 1991-01-10 | — | — | WO | disclosed |
| US-4977144-A | ADENOSINE AGONISTS | CIBA-GEIGY CORPORATION (US) | 1990-12-11 | — | — | US | disclosed |
| US-4874777-A | ANTIASTHMATICS | ELI LILLY AND COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| EP-0322582-A2 | 4-Heteroaryl-1,3-Benzodiazepines and 2-substituted-alpha-(heteroaryl)benzeneethanamines, a process for their preparation and their use us medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-07-05 | — | — | EP | disclosed |
| EP-0288190-A1 | Improvements in or relating to leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | disclosed |
| US-4470986-A | ISCHEMIA, SHOCK, THROMBOSIS | CIBA-GEIGY CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
| US-4444775-A | ENZYME INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1984-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | CA5A 1842/4885CA5B 2095/4885TSHR 3032/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | CA5A 675/4885CA5B 550/4885TSHR 493/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | CA5A 1842/4885CA5B 2095/4885TSHR 3032/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | CA5A 1842/4885CA5B 2095/4885TSHR 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.